Graft-versus-host disease: teaching old drugs new tricks at less cost
Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). Currently, more patients can receive SCT. This is attributed to the use of reduced intensity regimens and the use of different GVHD prophylaxis that breaks the barrier...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1225748/full |
| _version_ | 1827878155858214912 |
|---|---|
| author | Shatha Farhan Shernan G. Holtan |
| author_facet | Shatha Farhan Shernan G. Holtan |
| author_sort | Shatha Farhan |
| collection | DOAJ |
| description | Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). Currently, more patients can receive SCT. This is attributed to the use of reduced intensity regimens and the use of different GVHD prophylaxis that breaks the barrier of human leukocyte antigen, allowing an increase in the donor pool. Once an area with relatively few clinical trial options, there has been an increase in interest in GVHD prophylaxis and treatment, which has led to many US Food and Drug Administration (FDA) approvals. Although there is considerable excitement over novel therapies, many patients may not have access to them due to geographical or other resource constraints. In this review article, we summarize the latest evidence on how we can continue to repurpose drugs for GVHD prophylaxis and treatment. Drugs covered by our review include those that have been FDA approved for other uses for at least 15 years (since 2008); thus, they are likely to have generic equivalents available now or in the near future. |
| first_indexed | 2024-03-12T17:47:18Z |
| format | Article |
| id | doaj.art-2784da0d9c15442cb5e32c3615c64dbd |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T17:47:18Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2784da0d9c15442cb5e32c3615c64dbd2023-08-03T13:09:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-08-011410.3389/fimmu.2023.12257481225748Graft-versus-host disease: teaching old drugs new tricks at less costShatha Farhan0Shernan G. Holtan1Stem Cell Transplant and Cellular Therapy, Henry Ford Health, Detroit, MI, United StatesDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United StatesGraft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). Currently, more patients can receive SCT. This is attributed to the use of reduced intensity regimens and the use of different GVHD prophylaxis that breaks the barrier of human leukocyte antigen, allowing an increase in the donor pool. Once an area with relatively few clinical trial options, there has been an increase in interest in GVHD prophylaxis and treatment, which has led to many US Food and Drug Administration (FDA) approvals. Although there is considerable excitement over novel therapies, many patients may not have access to them due to geographical or other resource constraints. In this review article, we summarize the latest evidence on how we can continue to repurpose drugs for GVHD prophylaxis and treatment. Drugs covered by our review include those that have been FDA approved for other uses for at least 15 years (since 2008); thus, they are likely to have generic equivalents available now or in the near future.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1225748/fullgraft-versus-host diseasedrug repurposingpost-transplant cyclophosphamidebortezomibhuman chorionic gonadotropinsitagliptin |
| spellingShingle | Shatha Farhan Shernan G. Holtan Graft-versus-host disease: teaching old drugs new tricks at less cost Frontiers in Immunology graft-versus-host disease drug repurposing post-transplant cyclophosphamide bortezomib human chorionic gonadotropin sitagliptin |
| title | Graft-versus-host disease: teaching old drugs new tricks at less cost |
| title_full | Graft-versus-host disease: teaching old drugs new tricks at less cost |
| title_fullStr | Graft-versus-host disease: teaching old drugs new tricks at less cost |
| title_full_unstemmed | Graft-versus-host disease: teaching old drugs new tricks at less cost |
| title_short | Graft-versus-host disease: teaching old drugs new tricks at less cost |
| title_sort | graft versus host disease teaching old drugs new tricks at less cost |
| topic | graft-versus-host disease drug repurposing post-transplant cyclophosphamide bortezomib human chorionic gonadotropin sitagliptin |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1225748/full |
| work_keys_str_mv | AT shathafarhan graftversushostdiseaseteachingolddrugsnewtricksatlesscost AT shernangholtan graftversushostdiseaseteachingolddrugsnewtricksatlesscost |